Sagimet Biosciences (NASDAQ:SGMT) vs. DBV Technologies (NASDAQ:DBVT) Head-To-Head Analysis

DBV Technologies (NASDAQ:DBVT – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for DBV Technologies and Sagimet Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies 1 0 5 0 2.67
Sagimet Biosciences 2 0 9 0 2.64

DBV Technologies currently has a consensus price target of $45.25, suggesting a potential upside of 352.95%. Sagimet Biosciences has a consensus price target of $26.07, suggesting a potential upside of 164.68%. Given DBV Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe DBV Technologies is more favorable than Sagimet Biosciences.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares DBV Technologies and Sagimet Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DBV Technologies -5,392.17% -120.95% -88.35%
Sagimet Biosciences N/A -29.95% -27.71%

Valuation and Earnings

This table compares DBV Technologies and Sagimet Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV Technologies $5.64 million 111.38 -$146.95 million ($3.01) -3.32
Sagimet Biosciences $2.00 million 306.14 -$51.04 million ($1.19) -8.28

Sagimet Biosciences has lower revenue, but higher earnings than DBV Technologies. Sagimet Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DBV Technologies has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.43, indicating that its stock price is 243% more volatile than the S&P 500.

Summary

Sagimet Biosciences beats DBV Technologies on 10 of the 13 factors compared between the two stocks.

About DBV Technologies

(Get Free Report)

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company’s research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch. Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis.

About Sagimet Biosciences

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.